KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)

被引：13
|
作者：
Schmid, P.
Park, Y. H.
Munoz-Couselo, E.
Kim, S-B
Sohn, J.
Im, S-A
Holgado, E.
Foukakis, T.
Kuemmel, S.
Dent, R.
Yin, L.
Ding, Y.
Tryfonidis, K.
Cortes, J.
机构：
[1] Barts Canc Inst, Ctr Med Expt, London, England
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Yonsei Univ, Coll Med, Seoul, South Korea
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
[7] Ramon y Cajal Univ Hosp, Madrid, Spain
[8] Karolinska Univ Hosp, Radiumhemmet, Stockholm, Sweden
[9] Kliniken Essen Mitte, Essen, Germany
[10] Natl Canc Ctr, Singapore, Singapore
[11] Merck & Co Inc, Kenilworth, NJ USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-PD5-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 1b/2 Study to Evaluate Eribulin Mesylate (ERI) in Combination with Pembrolizumab (PEM) in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
    Tolaney, Sara
    Savulsky, Claudio
    Aktan, Gursel
    Xing, Dongyuan
    Almonte, Ana
    Karantza, Vasiliki
    Janevski, Mile
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 122 - 122
  • [32] Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
    Adams, Sylvia
    Schmid, Peter
    Rugo, Hope S.
    Winer, Eric P.
    Loirat, Delphine
    Awada, Ahmad
    Cescon, David W.
    Iwata, Hiroji
    Campone, Mario
    Nanda, Rita
    Hui, Rina
    Curigliano, Giuseppe
    Toppmeyer, Deborah
    O'Shaughnessy, Joyce
    Loi, Sherene
    Paluch-Shimon, Shani
    Card, Deborah
    Zhao, Jing
    Karantza, Vassiliki
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple-negative breast cancer (TNBC).
    Krivorotko, Petr
    Zhiltsova, Elena
    Gigolaeva, Larisa
    Emelyanov, Alexander
    Pesotskiy, Roman
    Yerechshenko, Sergey
    Nikolaev, Kirill
    Komyahov, Alexander
    Ivanova, Olga
    Tabagua, Tengiz
    Zernov, Konstantin
    Ivanov, Vadim
    Aseeva, Zalina
    Bessonov, Alexander
    Semiglazov, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC)
    Isakoff, Steven J.
    Tung, Nadine M.
    Yin, Jun
    Tayob, Nabihah
    Parker, Joanne
    Rosenberg, Julie
    Bardia, Aditya
    Spring, Laura
    Park, Hannah
    Collins, Maya
    Barry, William T.
    Severgnini, Mariano
    Peterkin, Doris
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [35] Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
    Melinda L. Telli
    Sara M. Tolaney
    Geoffrey I. Shapiro
    Mark Middleton
    Simon R. Lord
    Hendrik Tobias Arkenau
    Andrew Tutt
    Vandana Abramson
    Emma Dean
    Tufia C. Haddad
    Robert Wesolowski
    Jordi Ferrer-Playan
    Thomas Goddemeier
    Thomas Grombacher
    Jennifer Dong
    Patricia Fleuranceau-Morel
    Ivan Diaz-Padilla
    Ruth Plummer
    npj Breast Cancer, 8
  • [36] Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
    Telli, Melinda L.
    Tolaney, Sara M.
    Shapiro, Geoffrey, I
    Middleton, Mark
    Lord, Simon R.
    Arkenau, Hendrik Tobias
    Tutt, Andrew
    Abramson, Vandana
    Dean, Emma
    Haddad, Tufia C.
    Wesolowski, Robert
    Ferrer-Playan, Jordi
    Goddemeier, Thomas
    Grombacher, Thomas
    Dong, Jennifer
    Fleuranceau-Morel, Patricia
    Diaz-Padilla, Ivan
    Plummer, Ruth
    NPJ BREAST CANCER, 2022, 8 (01)
  • [37] KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
    Cortes, J.
    Lipatov, O.
    Im, S-A.
    Goncalves, A.
    Lee, K. S.
    Schmid, P.
    Tamura, K.
    Testa, L.
    Witzel, I.
    Ohtani, S.
    Zambelli, S.
    Harbeck, N.
    Andre, F.
    Dent, R.
    Zhou, X.
    Karantza, V.
    Mejia, J. A.
    Winer, E. P.
    ANNALS OF ONCOLOGY, 2019, 30 : 859 - +
  • [38] TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
    Vinayak, Shaveta
    Tolaney, Sara M.
    Schwartzberg, Lee Steven
    Mita, Monica M.
    McCann, Georgia Anne-Lee
    Tan, Antoinette R.
    Hendrickson, Andrea Elisabeth Wahner
    Forero-Torres, Andres
    Anders, Carey K.
    Wulf, Gerburg M.
    Dillon, Patrick M.
    Lynce, Filipa
    Zarwan, Corrine
    Erban, John Kalil
    Dezube, Bruce Jeffrey
    Zhou, Yinghui
    Buerstatte, Nathan
    Arora, Sujata
    Achour, Haroun
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth
    Kaufman, Peter A.
    Wilks, Sharon
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple-negative breast cancer (TNBC)
    Desmoulins, I.
    Chardin, D.
    Richard, C.
    Arnould, L.
    Boidot, R.
    Humbert, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S494 - S494
12345